Skip to main content
Premium Trial:

Request an Annual Quote

OncoDNA Closes $20.6M Funding Round

NEW YORK — Belgian molecular diagnostics firm OncoDNA said on Friday that it has closed a €19 million ($20.6 million) Series B financing round.

The round was led by Vesalius Biocapital III and Swisscanto Invest by Zürcher Kantonalbank. Other participants included SFPI-FPIM, CPH Bank, Inventures, Sambrinvest, Sofinim, SRIW, and undisclosed existing investors.

OncoDNA, which raised €7.7 million in 2016, said it will use the new funding to support its international growth, accelerate software development, and to expand its workforce.

"We [have] built a worldwide network of more than several thousand oncologists, OncoDNA Founder and CEO Jean-Pol Detiffe said in a statement. "Our next move is to connect molecular laboratories to our advanced data interpretation tools, which we pride ourselves on now being possible thanks to the support of our new investors."

About a year ago, OncoDNA released its OncoNTRK RNA sequencing assay for solid or liquid biopsies analysis of tumors with potential NTRK gene fusions. A few months before that, it updated its next-generation sequencing-based OncoDeep solid tumor analysis tool.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.